A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Inclusion Criteria:

• At least 18 years of age

• Completely removed melanoma by surgery performed within 12 weeks of randomization

• Advanced Melanoma

• Tumor tissue from the resected site of the disease must be available for biomarkeranalyses in order to be randomized

• Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Exclusion Criteria:

• Previous anti-cancer treatment

• Known hypersensitivity to monoclonal antibodies or to any of the excipients of thestudy drug

• Ocular or uveal melanoma or history of carcinomatosis meningitis

• History of auto-immune disease

• Subject has medical conditions requiring systemic immunosuppression with eithercorticosteroids or other immunosuppressive medications within 14 days of the firstdose of the investigational product

Other protocol-defined inclusion/exclusion criteria apply